Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Clinicians ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Psoriasis is a common skin condition that affects 125 million people worldwide, and about 30% of those living with psoriasis will also develop psoriatic arthritis. Medication has proven effective for ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

A GRAPPA working group highlighted the importance of screening for comorbidities to guide treatment selection among patients with psoriatic arthritis. Identifying important comorbidities and their ...

This article was originally published by Dermatology Times®. It has been lightly edited. Researchers found that treatment of psoriatic arthritis (PsA) varied depending on clinical specialization in ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

There are better treatments for psoriatic arthritis (PsA) today than ever, but not everyone has the same access to them or gets equal care. That’s because of disparities, or preventable differences, ...

Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

When you have psoriatic arthritis, following the treatment plan as prescribed is crucial for slowing the progression of the disease and easing symptoms. Adding complementary therapies to the overall ...